Enzon Pharmaceuticals, Inc. Returns Rights To Transplantation Product To Fresenius Biotech GmbH
Published: Jan 06, 2006
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Jan. 6, 2006--Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that it is returning its rights to ATG-Fresenius S to Fresenius Biotech GmbH, a subsidiary of the health care company Fresenius AG. ATG-Fresenius S is a polyclonal antibody preparation used for T-lymphocyte suppression to prevent organ graft rejection in organ transplant patients. The companies are committed to working together to assure a smooth transition for the current ongoing clinical trial for ATG-Fresenius S.